Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
February 21, 2019
DEER PARK, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will participate in a fireside chat
Read More
BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS’ EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY EYES ASSOCIATED WITH ALLERGIES
February 19, 2019
If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind EM-100 Has Been Submitted to the FDA for Review LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye
Read More
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
February 11, 2019
Transaction adds an additional potential 2019 product launch to Eton’s pipeline ET-202 NDA was submitted in December 2018 ; PDUFA date expected to be in Q4 2019 ET-203 NDA expected to be submitted by Q3 2019 DEER PARK, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution